Current Study
Chronic Rhinosinusitis | CEREN-2
A randomized, double-blind, placebo-controlled, parallel-group, 52 week Phase 3 trial to investigate the efficacy, safety, and tolerability of itepekimab in adult participants with inadequately controlled chronic rhinosinusitis with nasal polyps
Study Status
Closed
Duration
Up to 76 weeks
Clinic Visits
Up to 9
Phone Check-ins
Up to 20
Study Overview
Location
Spearwood
Phase
Phase 3
Study Duration
Up to 76 weeks
Main Entry Criteria
- Over 18 years of age
- History of chronic rhinosinusitis with nasal polyp(s) for at least 1 year
- Prior sinonasal surgery for nasal polyps
- Loss of smell or rhinorrhea (anterior/posterior)
There are additional eligibility requirements to enrol in this study. Our Study Doctor will review the study requirements and discuss your eligibility with you either over the telephone or at your first clinic visit.
Main Exclusion Criteria
Assessments
- ECG
- Blood pressure and pulse
- Blood and urine tests
- Nasal endoscopy
- CT Scan
- Questionnaires
- Spirometry for patients with Asthma
At a Glance
Clinic Visits
Up to 9
Phone Calls
Up to 20
Duration
Up to 76 weeks